Learn more on this topic: A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

What is the clinical relevance of FLT3 and IDH2 mutations in AML?

Sandy Kurtin, PhDc, ANP-C, AOCN

Sandy Kurtin, PhDc, ANP-C, AOCN, on treating patients with AML.

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.